In depth
Company research
The letter gives each trade in brief. Here is the complete analysis behind it: the business, the data, the competition, the risks and why we think the price is wrong.
CMPS Compass Pathways
Biotech · Psychiatry
Biotech · Psychiatry
COMP360: works, reproducibly but modestly. The edge is burden and first-mover timing.
A full read of the COMP360 psilocybin programme for treatment-resistant depression: the drug, both Phase 3 trials, every efficacy timepoint and p-value, safety, competitors, the FDA's psychedelic guidance and what the market is missing.
- Phase 3 patients
- 839
- Primary endpoint gap (MADRS)
- −3.6 / −3.8
- Expected FDA decision
- ~mid-Jan 2027
- Cash vs. debt
- $433M / $51M